EnginZyme
EnginZyme’s cell-free synthetic biology platform marries the efficiency of the chemical industry with the power and diversity of biology. The company was founded in Stockholm, Sweden. Since its start in 2014 it has used its technology to provide R&D services to leading companies in multiple industries, such as pharma, food, chemicals and flavors & fragrances. Its long-term aim is to make its cell-free synbio platform the foundation upon which the future chemical industry rests.
Sector
Industrial Biotech
Strategy
Industrial Biotech
Status
Active
Website
enginzyme.com
Related Articles
EnginZyme and Tetra Pak join forces to advance sustainable food & beverage production
EnginZyme Selected for Cleantech Group's 100 List of Companies Committed to Taking Action on the Climate Crisis
EnginZyme awarded as Technology Pioneer 2021 by World Economic Forum
EnginZyme Extends Series A to €11 Million to Advance Cell-Free Chemical Production Platform in Funding Round Led by Sweden’s Industrifonden
EnginZyme Secures €6.4 Million Series A Financing Round Led by Sofinnova Partners
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.